U.S. District Court Issues Decision Regarding CINVANTI® Patents
Rhea-AI Summary
Heron Therapeutics (Nasdaq:HRTX) announced that the U.S. District Court for the District of Delaware ruled on patent litigation with Azurity regarding CINVANTI (aprepitant) injectable emulsion, holding asserted claims of U.S. Patent Nos. 12,115,255 and 12,290,520 invalid.
According to Heron, the decision does not affect prior settlement agreements related to CINVANTI or APONVIE. The company intends to appeal to the U.S. Court of Appeals for the Federal Circuit and states it will continue defending its intellectual property rights.
AI-generated analysis. Not financial advice.
Positive
- Prior settlement agreements related to CINVANTI and APONVIE remain unaffected by the ruling
- Heron plans to appeal to the Federal Circuit, which specializes in patent disputes
Negative
- U.S. District Court held asserted claims of two CINVANTI patents invalid
Key Figures
Market Reality Check
Peers on Argus
HRTX is down 4.93% while four scanned biotech peers (e.g., MDWD, TNYA, SLN, NTHI) are all moving up, indicating a stock-specific reaction rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Q1 2026 earnings | Negative | -21.1% | Q1 2026 revenue decline and mix shift toward Acute Care franchise. |
| Apr 27 | Earnings call date | Neutral | +1.7% | Announcement of timing and access details for Q1 2026 results call. |
| Feb 26 | FY 2025 earnings | Positive | +11.1% | Full-year 2025 net revenue growth and 2026 guidance introduction. |
| Feb 17 | Earnings call date | Neutral | +3.5% | Scheduling of Q4 and full-year 2025 earnings call and webcast. |
| Jan 09 | Prelim revenue update | Positive | +9.4% | Preliminary Q4 2025 revenue with strong ZYNRELEF and CINVANTI contributions. |
News on financial performance and product revenue has typically led to price moves aligned with the news tone, with both positive and negative updates producing corresponding reactions.
Over the last six months, Heron’s key news flow has centered on revenue trends and franchise mix. Q4 and full-year 2025 results and preliminary Q4 2025 revenue, helped by ZYNRELEF and CINVANTI, were followed by positive share reactions. In contrast, Q1 2026 results showing lower net revenue and a shift away from Oncology Supportive Care coincided with a -21.05% move. Today’s CINVANTI patent decision adds legal risk on top of that revenue pressure, following earlier settlements referenced in recent earnings commentary.
Regulatory & Risk Context
Heron has an effective registration statement on Form S-3 dated 2025-09-09 that outlines broad risks related to commercialization, litigation, financing and governance for ZYNRELEF, APONVIE, CINVANTI, SUSTOL and pipeline assets. The filing remains active through 2028-09-09 with no recorded takedowns to date in the provided context.
Market Pulse Summary
The stock is down -6.9% following this news. A negative reaction despite Heron’s stated intent to appeal fits a pattern where adverse fundamentals or franchise pressures, such as the Q1 2026 revenue decline, have previously driven aligned selloffs. The decision that key CINVANTI patent claims are invalid adds legal uncertainty on top of existing Oncology Supportive Care weakness. Investors would likely monitor the appeal to the Federal Circuit and consider the active S-3 shelf from 2025-09-09 when assessing longer-term risk.
Key Terms
patent litigation regulatory
intellectual property rights regulatory
AI-generated analysis. Not financial advice.
After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal
CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable emulsion or APONVIE® (aprepitant) injectable emulsion. Heron intends to appeal the decision to the United States Court of Appeals for the Federal Circuit, a court that specializes in patent disputes.
“We are disappointed with this initial result of the litigation and will vigorously pursue our appeal and all available remedies, including equitable relief if necessary, as we continue to defend our intellectual property rights,” said Craig Collard, Chief Executive Officer of Heron.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding whether Heron appeals the decision and Heron’s ability to obtain a stay of market entry. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption “Risk Factors.” Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
